CN113024459A - Alvatinib mesylate intermediate impurity and preparation method thereof - Google Patents
Alvatinib mesylate intermediate impurity and preparation method thereof Download PDFInfo
- Publication number
- CN113024459A CN113024459A CN201911250408.3A CN201911250408A CN113024459A CN 113024459 A CN113024459 A CN 113024459A CN 201911250408 A CN201911250408 A CN 201911250408A CN 113024459 A CN113024459 A CN 113024459A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- impurity
- solution
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 239000012535 impurity Substances 0.000 title abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 9
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 claims abstract description 15
- 229950006605 varlitinib Drugs 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- QHTKIHWUKSVQSK-UHFFFAOYSA-N ClC1=CC=NC2=C(C=CC(=C12)OC)C(=O)N Chemical compound ClC1=CC=NC2=C(C=CC(=C12)OC)C(=O)N QHTKIHWUKSVQSK-UHFFFAOYSA-N 0.000 claims abstract description 6
- RFJVQGMBFQGZPV-UHFFFAOYSA-N 4-amino-3-chlorophenol;hydrochloride Chemical compound Cl.NC1=CC=C(O)C=C1Cl RFJVQGMBFQGZPV-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 239000005457 ice water Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003880 polar aprotic solvent Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 12
- -1 impurity B compound Chemical class 0.000 description 6
- 238000007865 diluting Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- OFQLBCBNNWFEPV-UHFFFAOYSA-N 4-(4-amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxamide Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC1=CC=C(N)C(Cl)=C1 OFQLBCBNNWFEPV-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- WXYIONYJZVWSIJ-UHFFFAOYSA-N acetonitrile;methanol;hydrate Chemical compound O.OC.CC#N WXYIONYJZVWSIJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960001429 lenvatinib mesylate Drugs 0.000 description 2
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a varlitinib mesylate intermediate impurity and a preparation method thereof. The preparation method of the impurity compound comprises the step of heating and reacting 4-amino-3-chlorophenol hydrochloride with 4-chloro-5-methoxyquinoline-8-carboxamide.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical chemistry, and relates to relative impurities of varlitinib mesylate and a preparation process thereof.
Background
The related statistical data show that the primary hepatocellular carcinoma is one of the common malignant tumors in the world, while China is a high-incidence country of the hepatocellular carcinoma, the morbidity and the mortality are respectively ranked in the third place and the second place in the malignant tumors, about 46.6 ten thousand people are attacked and 42.2 ten thousand people are killed each year, and the number of the attacked and dead people exceeds 50 percent of the whole world, thereby seriously threatening the physical health of people in China.
On day 17/8 in 2018, after the FDA approved the use of lenvatinib mesylate (lenviima), independently developed by wakame japan corporation, for first-line treatment of unresectable hepatocellular carcinoma (HCC), on day 4/9, the national drug administration also approved that lenvatinib mesylate was marketed in china and used for the same indications. Varenib mesylate (lenviima) is a multi-target drug that is an oral multi-RTK inhibitor that, in addition to inhibiting other angiogenesis and oncogenic signaling pathway related RTKs involved in tumor proliferation, including the receptors PDGFR, KIT and RET of platelet derived growth factor PDGF, is also capable of selectively inhibiting the kinase activity of Vascular Endothelial Growth Factor (VEGF) receptors (VEGFR 1, VEGFR2, VEGFR 3) and Fibroblast Growth Factor (FGF) receptors (FGFR1, FGFR2, FGFR 3).
According to the synthesis process of the first-step intermediate of the varlitinib mesylate, related impurities of the intermediate of the varlitinib mesylate can be generated through the following routes:
the target impurities are discovered and directionally synthesized, an analysis method of the target impurities is established, and the method has important significance for effectively controlling the quality of the raw material medicine of the varlitinib mesylate.
Disclosure of Invention
The invention provides an impurity B compound generated in the synthesis of an intermediate 4- (4-amino-3-chlorophenoxy) -7-methoxyquinoline-6-carboxamide of varlitinib mesylate and a preparation method of the impurity B compound. Since 4- (4-amino-3-chlorophenoxy) -7-methoxyquinoline-6-carboxamide is a key intermediate for preparing the ranvatinib mesylate, the quality control of the intermediate is very important for the quality control of the subsequent final product (the ranvatinib mesylate), and the impurity B compound has a genotoxicity warning structure, the monitoring of the impurity B compound is very important for improving and ensuring the quality of the ranvatinib mesylate.
In one embodiment of the invention, the invention provides a varlitinib mesylate intermediate impurity B, i.e., a compound of formula I, having the following chemical structural formula:
in another embodiment, the present invention provides a process for the preparation of the impurity B of varenib mesylate, a compound of formula I, comprising the steps of,
a) dissolving 4-amino-3-chlorophenol hydrochloride in a polar aprotic solvent, stirring for reaction in the presence of an inorganic strong base, and adding 4-chloro-5-methoxyquinoline-8-carboxamide for heating reaction;
b) after the reaction is finished, the mixed solution of the organic solvent is dripped into the solution, the natural cooling is started after the dripping is finished, and the ice-water bath cooling crystallization is started after the temperature is reduced to the room temperature. And after crystallization, starting suction filtration, washing a filter cake by using an organic solvent, and drying under reduced pressure to obtain an impurity B compound.
The further technical scheme is as follows: the polar aprotic solvent of step a) is dimethyl sulfoxide; the inorganic strong base is a potassium hydroxide solution with the mass fraction of 40-50%, and the dosage of the potassium hydroxide is 2.5-3.5eq of 4-chloro-5-methoxyquinoline-8-carboxamide; the heating reaction temperature is 60-80 ℃, and the heating reaction time is 12-21 h.
In the step b), the organic solvent dropped into the reaction solution is mixed solution of acetone and purified water in a volume ratio of 1:2, the organic solvent used for washing is acetone, and the washing is carried out for 2 to 3 times; the room temperature is 20-30 ℃, and the temperature is reduced to 0-10 ℃ in an ice water bath.
The invention also aims to provide a bulk drug containing the pharmaceutical drug containing the methanesulfonic acid lunatinib and the compound shown in the formula I, wherein the content of the compound shown in the formula I or the salt thereof relative to the methanesulfonic acid lunatinib is lower than 60ppm, preferably lower than 10ppm or lower.
The invention also relates to the use of a compound of formula I or a salt thereof as a standard or control.
The beneficial results of the invention are:
the impurity B compound (compound shown in the formula I) of the key intermediate of the varlitinib mesylate and the preparation method thereof are prepared for the first time, the purity of the impurity B of the varlitinib mesylate prepared by the method is more than 98%, and the impurity B can be used for quality research and production quality control of the varlitinib mesylate. Therefore, the compound can be used as a standard substance and a reference substance for controlling the quality of the intermediate 4- (4-amino-3-chlorophenoxy) -7-methoxyquinoline-6-carboxamide and the quality of the methanesulfonic acid lunvatinib, and ensuring the quality of the key intermediate so as to ensure the quality of the final methanesulfonic acid lunvatinib product.
Drawings
FIG. 1 shows an HPLC chromatogram of the impurity B of varlitinib mesylate.
FIG. 2 shows the mass spectrum of the impurity B of varlitinib mesylate.
FIG. 3 shows the hydrogen spectrum of impurity B of varlitinib mesylate.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1 preparation of Lunvatinib mesylate impurity B
4-amino-3-chlorophenylate (9.89 g, 54.85 mmol) and 90 mL of DMSO were placed in a 250 mL three-necked flask, and the mixture was stirred at room temperature for 20 to 30 min to completely dissolve the solid. Slowly dripping 40% potassium hydroxide solution, and stirring and reacting for 15-25 min after finishing the dripping. 4-chloro-5-methoxyquinoline-8-carboxamide (10 g, 42.26 mmol) was added to the reaction mixture, the temperature was raised to 60-70 ℃ and the reaction was allowed to incubate for 15 h. After completion of the reaction, a mixed solvent of 50mL of acetone and 100mL of purified water was added dropwise to the reaction mixture. After the dropwise addition, the temperature is naturally reduced, and then the temperature is reduced and crystallization is carried out by using an ice water bath. After crystallization, the mixture is filtered, and dried under reduced pressure to obtain 13.5 g of impurity B, wherein the yield is 93.00 percent, and the purity is 98.73 percent.
HPLC purity chromatographic conditions were as follows:
the instrument comprises the following steps: high performance liquid chromatograph
A chromatographic column: YMC-Pack Pro C184.6 with 150mm 5 μm
Sample introduction amount: 20 mu l
Flow rate: 1ml/min
Detection wavelength: 265nm
Column temperature: 25 deg.C
Mobile phase: gradient elution was performed using methanol-water (50: 950) as mobile phase A and acetonitrile-methanol-water (700: 200: 100) as mobile phase B according to the following table
Time (min) | A(%) | B(%) |
0 | 85 | 15 |
5 | 85 | 15 |
35 | 55 | 45 |
45 | 10 | 90 |
50 | 10 | 90 |
50.01 | 85 | 15 |
60 | 85 | 15 |
The purity of the obtained sample was 98.73% by checking according to the above conditions, and the content value was 98.36% by calculation after the loss on drying and the residue were measured.
And (5) detecting by hydrogen spectrum mass spectrum, and confirming the structure to be consistent with the structure of the target molecule.
MS (m/z): 344[ M + H ] +. See FIG. 2
1H NMR (600 MHz, DMSO-d6) delta 10.36 (d, J = 4.5 Hz, 1H), 8.70 (d, J = 5.3 Hz, 1H), 8.60 (d, J = 8.6 Hz, 1H), 7.67 (d, J = 4.5 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.16 (d, J = 2.5 Hz, 1H), 6.97-6.89 (m, 2H), 6.66 (d, J = 5.3 Hz, 1H), 5.43 (s, 2H), 3.97 (s, 3H); see FIG. 3.
The impurities are detected by adopting a high performance liquid chromatography, and the detection method comprises the following steps:
1. chromatographic conditions are as follows:
the instrument comprises the following steps: high performance liquid chromatograph
A chromatographic column: YMC-Pack Pro C184.6 mm, 5 μm
Sample introduction amount: 20 mu l
Flow rate: 1ml/min
Detection wavelength: 265nm
Column temperature: 40 deg.C
Mobile phase: gradient elution was performed using methanol-water (50: 950) as mobile phase A and acetonitrile-methanol-water (700: 200: 100) as mobile phase B according to the following table
Time (min) | A(%) | B(%) |
0 | 90 | 10 |
35 | 55 | 45 |
45 | 10 | 90 |
50 | 10 | 90 |
50.01 | 90 | 10 |
60 | 90 | 10 |
2. The determination method comprises the following steps:
control solution: taking 10mg of impurity B, precisely weighing, placing in a 100ml measuring flask, dissolving with methanol, diluting to scale, and shaking up to obtain impurity stock solution; precisely measuring 1ml of each impurity stock solution, putting the impurity stock solution into a 20ml measuring flask, diluting the impurity stock solution to a scale with a diluent, and shaking up to obtain an impurity mixed solution; precisely measuring 1ml of impurity mixed solution, placing the impurity mixed solution into a 100ml measuring flask, diluting the impurity mixed solution to a scale with a diluent, and shaking up to obtain an impurity reference solution.
Test solution: weighing about 25mg of a sample to be tested, precisely weighing, placing in a 50ml measuring flask, adding about 30ml of diluent, ultrasonically dissolving, diluting with the diluent to scale, shaking up, precisely weighing 5ml, placing in a 25ml measuring flask, diluting with the diluent to scale, and shaking up.
And precisely measuring 20 mul of the solution, respectively injecting the solution into a liquid chromatograph, and recording a chromatogram.
3. Formula for calculation
Calculated by peak area external standard method
In the formula, CTo pair-control content;
Ato pair-peak area of control solution;
A-peak area of the test solution;
V-the dilution volume of the test solution, ml;
V to pair-dilution volume of control solution, ml;
m-sample weighing of reference substance, mg;
m-sample weight of the sample, mg.
Three batches of intermediate 4- (4-amino-3-chlorophenoxy) -7-methoxyquinoline-6-carboxamide were tested as described above, with impurity B contents of 80ppm, 60ppm and 45 ppm respectively. And detecting the corresponding three batches of final product varlitinib mesylate, wherein the contents of the impurity B are respectively 10ppm, 6ppm and 0ppm (lower than detection limit).
Finally, the above embodiments are only used to illustrate the spirit of the technical solution of the present invention and are not limited. While the present invention has been described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (9)
2. a process for preparing a compound of formula I, comprising the steps of:
a) dissolving 4-amino-3-chlorophenol hydrochloride in a polar aprotic solvent, stirring for reaction in the presence of an inorganic strong base, and adding 4-chloro-5-methoxyquinoline-8-carboxamide for heating reaction;
b) after the reaction is finished, dropwise adding the mixed solution of the organic solvent into the solution, cooling after the dropwise adding is finished, cooling to room temperature, cooling in an ice water bath for crystallization, filtering after the crystallization is finished, washing a filter cake with the organic solvent, and drying under reduced pressure to obtain the compound of the formula I.
3. The method of claim 2, wherein the polar aprotic solvent is dimethyl sulfoxide.
4. The method of claim 2, wherein the inorganic strong base is a potassium hydroxide solution with a mass fraction of 40% to 50%, and the amount of the potassium hydroxide is 2.5 to 3.5eq of 4-chloro-5-methoxyquinoline-8-carboxamide.
5. The method of claim 2, wherein the heating reaction temperature is 60-80 ℃, and the heating reaction time is 12-21 h.
6. The method according to claim 2, wherein the organic solvent added dropwise to the reaction solution in step b) is a mixture of acetone and purified water at a volume ratio of 1:2, and the organic solvent used for washing is acetone, and the washing is performed 2 to 3 times.
7. The method of claim 2, wherein the room temperature in step b) is 20-30 ℃, and the temperature of the ice water bath is reduced to 0-10 ℃.
8. Use of a compound of formula I according to claim 1 or a salt thereof as a control or standard.
9. A raw material drug of varlitinib mesylate, wherein the content of a compound shown in a formula I or a salt thereof is not more than 60 ppm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911250408.3A CN113024459A (en) | 2019-12-09 | 2019-12-09 | Alvatinib mesylate intermediate impurity and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911250408.3A CN113024459A (en) | 2019-12-09 | 2019-12-09 | Alvatinib mesylate intermediate impurity and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113024459A true CN113024459A (en) | 2021-06-25 |
Family
ID=76451162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911250408.3A Pending CN113024459A (en) | 2019-12-09 | 2019-12-09 | Alvatinib mesylate intermediate impurity and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113024459A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109851556A (en) * | 2019-03-18 | 2019-06-07 | 扬子江药业集团有限公司 | Logical sequence cuts down the preparation method for Buddhist nun or its mesylate drug impurity |
CN110283122A (en) * | 2019-06-26 | 2019-09-27 | 石药集团中奇制药技术(石家庄)有限公司 | A kind of high-purity logical sequence cuts down the preparation method for Buddhist nun and its salt |
-
2019
- 2019-12-09 CN CN201911250408.3A patent/CN113024459A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109851556A (en) * | 2019-03-18 | 2019-06-07 | 扬子江药业集团有限公司 | Logical sequence cuts down the preparation method for Buddhist nun or its mesylate drug impurity |
CN110283122A (en) * | 2019-06-26 | 2019-09-27 | 石药集团中奇制药技术(石家庄)有限公司 | A kind of high-purity logical sequence cuts down the preparation method for Buddhist nun and its salt |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102604876B1 (en) | Synthesis of MCL-1 inhibitors | |
CN103992336B (en) | Oxa-or thia evodiamine anti-tumor derivant and preparation method thereof | |
JP7476115B2 (en) | Novel salts and crystals | |
EA038195B1 (en) | Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and use thereof for the treatment of kidney and liver cancer | |
WO2014008794A1 (en) | Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof | |
US20070203178A1 (en) | Crystalline solvates of apixaban | |
US10689361B2 (en) | Quinoline derivative and use thereof | |
WO2019228485A1 (en) | New crystal form of lenvatinib mesylate and preparation method therefor | |
WO2024037138A1 (en) | Phloretin-isoniazid cocrystal and preparation method therefor | |
CN102219797A (en) | N-heterocyclic carbene annular metal complexes, preparation method and purpose thereof | |
JP2023089169A (en) | Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof | |
EP3805229A1 (en) | Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof | |
CN111479809A (en) | Crystal form and salt form of TGF- β RI inhibitor and preparation method thereof | |
JP2021508319A (en) | Salt form as an Akt inhibitor and its crystal form | |
CN116120347B (en) | Crystal form of aromatic heterocyclic compound, composition, preparation method and application thereof | |
JP2022537919A (en) | Method for Synthesizing Furoimidazopyridine Compounds, Polymorphs and Polymorphs of Salts | |
CN108530436B (en) | Pyrazole compound and preparation method and application thereof | |
CN103554120B (en) | Preparation method of 3, 3-spiro (2-tetrahydrofuranyl)-oxindole polycyclic compound | |
CN113024459A (en) | Alvatinib mesylate intermediate impurity and preparation method thereof | |
JP2022520629A (en) | FGFR inhibitor compound in solid form and method for producing the same | |
WO2021213453A1 (en) | Lenvatinib mesylate crystal form xi and preparation method therefor | |
CN103554121B (en) | 3,3-spiro (2-tetrahydrofuranyl)-oxindole polycyclic compound and application thereof | |
CN110423234B (en) | Thiosemicarbazone derivative containing indole fragment and preparation method and application thereof | |
CN105753860A (en) | Beta-carboline alkaloid and application thereof in preparation of antitumor drugs | |
CN110194741B (en) | 4-benzoyl piperazine-3-nitro-1, 8-naphthalimide derivative and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210625 |